Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Circulating tumor DNA (ctDNA) may provide a prediction of treatment response, but could be impacted by tumor heterogeneity. Here, the authors investigate ctDNA in CDK4/6 inhibitor treatment in advanced breast cancer, finding ctDNA levels predict progression-free survival and anticipate clonal select...
Guardado en:
Autores principales: | Ben O’Leary, Sarah Hrebien, James P. Morden, Matthew Beaney, Charlotte Fribbens, Xin Huang, Yuan Liu, Cynthia Huang Bartlett, Maria Koehler, Massimo Cristofanilli, Isaac Garcia-Murillas, Judith M. Bliss, Nicholas C. Turner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe55104b6a3946c08222bef99156c284 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Genomic profile of advanced breast cancer in circulating tumour DNA
por: Belinda Kingston, et al.
Publicado: (2021) -
Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016) -
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
por: Belinda Kingston, et al.
Publicado: (2021) -
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo KA, et al.
Publicado: (2014) -
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: R.K. Ismail, et al.
Publicado: (2021)